WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001085789) EXTRACELLULAR DOMAIN OF RYK PROTEIN FOR REGULATING ANGIOGENESIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/085789    International Application No.:    PCT/US2001/015043
Publication Date: 15.11.2001 International Filing Date: 09.05.2001
Chapter 2 Demand Filed:    04.12.2001    
IPC:
A61K 38/00 (2006.01), C07K 14/71 (2006.01)
Applicants: BAYER CORPORATION [US/US]; 800 Dwight Way P.O. Box 1986 Berkeley, CA 94701-1986 (US) (For All Designated States Except US).
ROCZNIAK, Steve [CA/US]; (US) (For US Only).
DUBOIS-STRINGFELLOW, Nathalie, A. [FR/US]; (US) (For US Only).
ZOLOTOREV, Alya [US/US]; (US) (For US Only)
Inventors: ROCZNIAK, Steve; (US).
DUBOIS-STRINGFELLOW, Nathalie, A.; (US).
ZOLOTOREV, Alya; (US)
Agent: SHAW, Melissa, A.; Bayer Corporation 800 Dwight Way P.O. Box 1986 Berkeley, CA 94701-1986 (US)
Priority Data:
09/568,783 10.05.2000 US
Title (EN) EXTRACELLULAR DOMAIN OF RYK PROTEIN FOR REGULATING ANGIOGENESIS
(FR) PROCEDE DE REGULATION DE L'ANGIOGENESE AU MOYEN DE LA PROTEINE RYK
Abstract: front page image
(EN)Ryk protein was found to have a novel activity in regulating angiogenesis. New variant Ryk proteins were constructed that were useful in modulating the capillary forming activity of endothelial cells. Variant Ryk proteins, may be employed as therapeutics in diseases such as cancer, wound healing, diabetic retinopathies, macular degeneration, and cardiovascular diseases, and other diseases or clinical conditions where angiogenesis is relevant to the causation or treatment of the disease.
(FR)On a découvert que la protéine Ryk présentait une nouvelle activité dans la régulation de l'angiogénèse. On a construit des nouveaux variants des protéines Ryk qui sont utiles dans la modulation de l'activité de formation des capillaires des cellules endothéliales. On peut utiliser des protéines Ryk variantes en tant qu'agents thérapeutiques dans des maladies telles que le cancer, la cicatrisation des plaies, des rétinopathies diabétiques, la dégénérescence de la macula et des maladies cardio-vasculaires, ainsi que d'autres maladies ou états cliniques dans lesquels l'angiogénèse joue un rôle important dans les causes à l'origine de la maladie et le traitement de celle-ci.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)